Date: 2016-08-09
Type of information: Services contract
Compound: small molecules for the treatment of neurodegenerative diseases
Company: Selvita (Poland) University of California, San Francisco (UCSF) (USA - CA)
Therapeutic area: Neurodegenerative diseases
Type agreement: collaboration - services contract
Action mechanism:
Disease: neurodegenerative diseases
Details:
- • On August 9, 2016, Selvita Inc., the US subsidiary of Selvita, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF). The project will be conducted with the Institute for Neurodegenerative Diseases at UCSF. Within the scope of the project, Selvita will be responsible for the chemical synthesis, purification, structure determination, and purity analysis of small molecules for the treatment of neurodegenerative diseases. The project will focus on the synthesis of new derivatives, constituting potential new therapeutics with improved pharmacological properties.
- This project was preceded by a thorough evaluation and pilot projects involving medicinal chemistry as well as ADME projects, which Selvita successfully completed. The contract will be carried out from 2016 to 2019.
- Selvita’s San Francisco Bay Area office was founded in San Bruno, in September 2015 and is dedicated to the support of Selvita business partners on the West Coast of the US. The office is located at 1001 Bayhill Drive, San Bruno, California.
Financial terms:
Latest news:
Is general: Yes
